Skip to main content

Table 2 Lower respiratory tract infections in bronchiectasis concomitant to inflammatory diseases, according to the rheumatic disease-modifying treatment

From: Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

 

All treatments

Non-biologic DMARDs

Biologic DMARDs

Etanercept

Adalimumab

Infliximab

Abatacept

Rituximab

N periods of treatment of the rheumatologic disease

98

40

58

19

4

12

10

9

Total N infections

93

16

77

13

3

34

23

4

N patient-years of follow-up

194

98

96

33

1

30

17

12

N infections per patient-year, mean (SD) [95% CI]

0.8 (1.4) [0-3.6]

0.2 (0.5) [0-1.2]

1.2 (1.6) [0-4.3]

0.8 (1.4)

[0-3.5]

2.3 (2.1)

[0-6.4]

1.9 (1.6)

[0-5.0]

1.9 (1.9)

[0-5.6]

0.3 (0.7) [0-1.7]

  1. One patient was treated by anakinra ans is not detailed in the table